The historical rank and industry rank for Coherus Oncology's Net Margin % or its related term are showing as below:
FRA:8C5'
s Net Margin % Range Over the Past 10 Years
Min: -15306.56 Med: -66.98 Max: 398.43
Current: 397.3
FRA:8C5's Net Margin % is ranked better than 98.94% of 943
companies
in the Biotechnology industry
Industry Median: -89.33
vs FRA:8C5: 397.30
Coherus Oncology (FRA:8C5) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Coherus Oncology Net Margin % Related Terms
Coherus Oncology Net Margin % Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs TARA, KPTI, CNTN: Net Margin % Comparison
For the Biotechnology subindustry, Coherus Oncology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Net Margin % distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a Net Margin % of -311.35% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #10 out of 943 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Coherus Oncology's Net Margin % too high?
Coherus Oncology's current Net Margin % is -311.35%. Based on the distribution chart, Coherus Oncology ranks #10 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Coherus Oncology has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Net Margin % compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #10 out of 943 companies for Net Margin %. This places Coherus Oncology in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Coherus Oncology and its competitors. Coherus Oncology's current Net Margin % is -311.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.69, compared to a current price of €1.26 — trading 82.2% above its estimated fair value. The current Net Margin % is -311.35%. Coherus Oncology's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Net Margin % is -311.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.26 is trading 82.2% above its estimated GF Value™ of €0.69.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
Net Margin %: -311.35%
GF Value™: €0.69 vs. price of €1.26 (82.2% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
45GF Score
Get the complete analysis for FRA:8C5
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
